Publisher
Springer Science and Business Media LLC
Subject
Psychiatry and Mental health,Clinical Neurology,Dermatology,General Medicine
Reference5 articles.
1. EMA, Mayzent (2020) https://www.ema.europa.eu/en/medicines/human/EPAR/mayzent. Accessed 11 Dec 2019
2. FDA. Mayzent (siponimod) label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209884s000lbl.pdf. Initial U.S. Approval: 2019
3. Kappos L, Bar-Or A, Cree BAC, Clinical EXPAND, Investigators. et al (2018) Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 391(10127):1263–1273
4. FDA. Gilenya (fingolimod) label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022527s008lbl.pdf. Initial U.S. Approval: 2010
5. Dumitrescu L, Constantinescu CS, Tanasescu R (2019) Siponimod for the treatment of secondary progressive multiple sclerosis. Expert Opin Pharmacother 20(2):143–150
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献